<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354679</url>
  </required_header>
  <id_info>
    <org_study_id>06-013</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-06013</secondary_id>
    <nct_id>NCT00354679</nct_id>
  </id_info>
  <brief_title>Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer</brief_title>
  <official_title>Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
      ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others
      interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the
      growth of esophageal cancer by blocking blood flow to the tumor. Radiation therapy uses
      high-energy x-rays to kill tumor cells. Giving chemotherapy and monoclonal antibody therapy
      together with radiation therapy before surgery may make the tumor smaller and reduce the
      amount of normal tissue that needs to be removed. Giving bevacizumab after surgery may kill
      any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying how well giving irinotecan, cisplatin, and
      bevacizumab together with radiation therapy followed by surgery and bevacizumab works in
      treating patients with locally advanced esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the toxicity and safety of bevacizumab when given together with cisplatin,
           irinotecan hydrochloride, and radiotherapy followed by surgery and adjuvant bevacizumab
           in patients with locally advanced esophageal adenocarcinoma.

      Secondary

        -  Observe the rate of pathologic complete response in patients treated with this regimen.

        -  Observe overall survival, disease-free survival, and patterns of failure in these
           patients.

        -  Clarify toxicity and tolerability of this regimen.

        -  Evaluate pre-treatment levels of vascular endothelial growth factor in patient serum as
           a corollary of response to this regimen.

        -  Correlate serum proteomics data with complete pathologic response.

      OUTLINE: This is a nonrandomized, open-label study.

        -  Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan
           hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive
           bevacizumab IV over 30-90 minutes on days 1 and 22.

        -  Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan
           hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also
           receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external
           beam radiotherapy 5 days a week for 6 weeks beginning on day 43.

        -  Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and
           radiotherapy.

        -  Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab
           IV over 30-90 minutes every 3 weeks for 6 months.

      Blood samples are obtained at baseline, after finishing chemoradiotherapy, and prior to
      maintenance therapy and are examined by the matrix-assisted laser-desorption ionization time
      of flight (MALDI-TOF) mass spectometry for proteomic profiling.

      After completion of study treatment, patients are followed every 3 months for 1 year, every 4
      months for 1 year, every 6 months for 3 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Safety and Toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.
Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.
Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction

               -  T1, N1, M0 or T2-4, any N, M0 esophageal carcinoma that is surgically resectable

               -  Disease must be clinically limited to the esophagus or gastroesophageal junction

                    -  If tumor extends below the gastroesophageal junction into the proximal
                       stomach, 50% of the tumor must involve the distal esophagus or
                       gastroesophageal junction

          -  No carcinoma in situ (Tis) or tumors determined to be T1, N0 after endoscopy,
             endoscopic ultrasound, or CT scan

          -  No gastric cancers with minor involvement of the gastroesophageal junction or distal
             esophagus

          -  No metastatic disease, including any of the following:

               -  M1a celiac or supraclavicular disease

               -  Positive malignant cytology of the pleura, pericardium, or peritoneum

               -  Radiographic evidence of distant organ involvement, including lung, liver, bone,
                  or brain

               -  No involvement of nonregional lymph nodes including supraclavicular or celiac
                  lymph node metastases that cannot be contained within a radiation field

          -  No biopsy-proven tumor invasion of the tracheobronchial tree or presence of
             tracheoesophageal fistula

          -  No recurrent laryngeal nerve or phrenic nerve paralysis

          -  No CNS or brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  INR ≤ 1.5 (except for patients requiring full-dose warfarin while on bevacizumab)

          -  Creatinine ≤ 1.5 mg/dL

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST and ALT &lt; 2.5 times normal

          -  Urine protein ≤ 1+ by urinalysis OR &lt; 1 g of protein by 24-hour urine collection

          -  Calcium &lt; 12 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other prior malignancy (except for basal cell or squamous cell carcinoma of the
             skin, in situ cervical carcinoma, or superficial transitional cell bladder carcinoma)
             diagnosed and/or treated within the past 3 years

          -  No known Gilbert's disease

          -  No clinically significant hearing loss

          -  No known hypersensitivity to bevacizumab or other study drugs

          -  No severe comorbid conditions, including any of the following:

               -  Severe uncontrolled diabetes

               -  Prior stroke or cerebrovascular disease

               -  Uncontrolled infection

               -  Nonmalignant illness that precludes study treatment

          -  No history of serious systemic disease, including any of the following:

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled hypertension (i.e., blood pressure &gt; 160/110 mm Hg on medication)

               -  Unstable angina

               -  New York Heart Association class II-IV congestive heart failure

               -  Unstable symptomatic arrhythmia requiring medication

                    -  Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal
                       supraventricular tachycardia) allowed

               -  Peripheral vascular disease ≥ grade 2

          -  No significant traumatic injury within the past 28 days

          -  No evidence of bleeding diathesis or coagulopathy

          -  No other concurrent medical or psychiatric condition or disease that would preclude
             study participation

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy

          -  Recovered from prior oncologic or other major surgery

          -  No major surgery or open biopsy within the past 28 days

          -  No fine-needle aspiration or core biopsies within the past 7 days

          -  At least 1 week since prior and no concurrent participation in another experimental
             drug study (unless Genentech sponsored)

          -  No other concurrent major surgery

          -  No other concurrent chemotherapy

          -  No concurrent sargramostim (GM-CSF)

          -  No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital,
             Hypericum perforatum (St. John's wort), or other antiepileptic medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Safety and Toxicity</title>
        <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
            <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety and Toxicity</title>
          <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS cerebrovascular ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death not associated with CTCAE term- Death NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Esophagitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhage, CNS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection, other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (total WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/granulocytes (ANC/AGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Chest wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Extremity-limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perforation, GI- Jejunum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate, low (hypophosphatemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low (hypokalemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/embolism (vascular access-related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/thrombus/embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Perforation, GI- Jejunum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term- Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Prothrombin time international normalized ratio</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia (Difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Glucose, low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Magnesium, low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sodium, low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Trglycrde, high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Ilson</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4183</phone>
      <email>ilsond@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

